-
1
-
-
19344364880
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials
-
Early Breast Cancer Trialists Collaborative Group
-
Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365:1687-717.
-
(2005)
Lancet
, vol.365
, pp. 1687-1717
-
-
-
2
-
-
34347395733
-
Trastuzumab: Mechanism of action and use in clinical practice
-
Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39-51.
-
(2007)
N Engl J Med
, vol.357
, pp. 39-51
-
-
Hudis, C.A.1
-
3
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1997; 235:177-82.
-
(1997)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
-
4
-
-
0032538040
-
ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
-
Paik S, Bryant J, Park C, et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90:1361-70.
-
(1998)
J Natl Cancer Inst
, vol.90
, pp. 1361-1370
-
-
Paik, S.1
Bryant, J.2
Park, C.3
-
5
-
-
0034694659
-
HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
-
Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000; 92:1991-98.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 1991-1998
-
-
Paik, S.1
Bryant, J.2
Tan-Chiu, E.3
-
6
-
-
0003298825
-
HER2 expression and anthracy-cline effect: Results from the Naple GUN 3 randomized trial
-
Abstract 133
-
De Laurentiis M, Caputo F, Massarelli E, et al. HER2 expression and anthracy-cline effect: results from the Naple GUN 3 randomized trial. Proc Am Soc Clin Oncol 2001; 20:34a (Abstract 133).
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
-
-
De Laurentiis, M.1
Caputo, F.2
Massarelli, E.3
-
7
-
-
0036091354
-
HER-2 amplification and topoisom-erase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclo-phosphamide, methotrexate, and 5-fluorouracil
-
Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisom-erase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclo-phosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002; 8:1107-16.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 1107-1116
-
-
Di Leo, A.1
Gancberg, D.2
Larsimont, D.3
-
8
-
-
0037317929
-
HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer
-
Moliterni A, Menard S, Valagussa P, et al. HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol 2003; 21:458-62.
-
(2003)
J Clin Oncol
, vol.21
, pp. 458-462
-
-
Moliterni, A.1
Menard, S.2
Valagussa, P.3
-
9
-
-
32944475493
-
Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclo-phosphamide, epirubicin, and fluorouracil
-
Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclo-phosphamide, epirubicin, and fluorouracil. J Clin Oncol 2005; 23:7483-90.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7483-7490
-
-
Knoop, A.S.1
Knudsen, H.2
Balslev, E.3
-
10
-
-
32944459739
-
HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/ methotrex-ate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: Long-term results
-
Colozza M, Sidoni A, Mosconi AM, et al. HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/ methotrex-ate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results. Clin Breast Cancer 2005; 6:253-9.
-
(2005)
Clin Breast Cancer
, vol.6
, pp. 253-259
-
-
Colozza, M.1
Sidoni, A.2
Mosconi, A.M.3
-
11
-
-
33646681444
-
HER2 and responsiveness of breast cancer to adjuvant chemotherapy
-
Pritchard KI, Shepherd LE, O'Malley F P, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354:2103-11.
-
(2006)
N Engl J Med
, vol.354
, pp. 2103-2111
-
-
Pritchard, K.I.1
Shepherd, L.E.2
O'Malley, F.P.3
-
12
-
-
0024522502
-
Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience
-
Fisher B, Redmond C, Wickerham DL, et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 1989; 7:572-82.
-
(1989)
J Clin Oncol
, vol.7
, pp. 572-582
-
-
Fisher, B.1
Redmond, C.2
Wickerham, D.L.3
-
13
-
-
0026501239
-
A consumers' guide to subgroup analyses
-
Oxman AD, Guyatt GH. A consumers' guide to subgroup analyses. Ann Intern Med 1992; 116:78-84.
-
(1992)
Ann Intern Med
, vol.116
, pp. 78-84
-
-
Oxman, A.D.1
Guyatt, G.H.2
-
14
-
-
12344327497
-
Can meta-analysis help target interventions at individuals most likely to benefit?
-
Thompson SG, Higgins JPT. Can meta-analysis help target interventions at individuals most likely to benefit? Lancet 2005; 365:341-6.
-
(2005)
Lancet
, vol.365
, pp. 341-346
-
-
Thompson, S.G.1
Higgins, J.P.T.2
-
15
-
-
38049103907
-
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials
-
Gennari A, Sormani M P, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008; 100:16-20.
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 16-20
-
-
Gennari, A.1
Sormani, M.P.2
Pronzato, P.3
-
16
-
-
43149115407
-
-
Dhesy-Thind B.Pritchard KI, Messersmith H, et al. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat 2008; 109:209-29.
-
Dhesy-Thind B.Pritchard KI, Messersmith H, et al. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat 2008; 109:209-29.
-
-
-
-
17
-
-
21144435932
-
Adjuvant docetaxel for node-positive breast cancer
-
Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352:2302-13.
-
(2005)
N Engl J Med
, vol.352
, pp. 2302-2313
-
-
Martin, M.1
Pienkowski, T.2
Mackey, J.3
-
18
-
-
33645727496
-
Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy
-
Kostopoulos I, Arapantoni-Dadioti P, Gogas H, et al. Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Breast Cancer Res Treat 2006; 96:251-61.
-
(2006)
Breast Cancer Res Treat
, vol.96
, pp. 251-261
-
-
Kostopoulos, I.1
Arapantoni-Dadioti, P.2
Gogas, H.3
-
19
-
-
35248895346
-
The cancer and leukemia group: Her2 and response to paclitaxel in node-positive breast cancer
-
Hayes D F, Thor AD, Dressler LG, et al. The cancer and leukemia group: her2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357:1496-506.
-
(2007)
N Engl J Med
, vol.357
, pp. 1496-1506
-
-
Hayes, D.F.1
Thor, A.D.2
Dressler, L.G.3
-
20
-
-
0032190561
-
Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme
-
Burden DA, Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biochim Biophys Acta 1998; 1400:139-54.
-
(1998)
Biochim Biochim Biophys Acta
, vol.1400
, pp. 139-154
-
-
Burden, D.A.1
Osheroff, N.2
-
21
-
-
17944375163
-
HER2 and topo-isomerase alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide
-
Di Leo A, Larsimont D, Gancberg D, et al. HER2 and topo-isomerase alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001; 12:1081-9.
-
(2001)
Ann Oncol
, vol.12
, pp. 1081-1089
-
-
Di Leo, A.1
Larsimont, D.2
Gancberg, D.3
-
22
-
-
33749622561
-
Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF CEF in premenopausal women with node positive breast cancer
-
O'Malley F P, Chia S, Tu D, et al. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF CEF in premenopausal women with node positive breast cancer. Breast Cancer Res Treat 2006; 100:S18.
-
(2006)
Breast Cancer Res Treat
, vol.100
-
-
O'Malley, F.P.1
Chia, S.2
Tu, D.3
-
23
-
-
84898694718
-
-
O'Malley F P, Chia S, Tu D, et al. Prognostic and predictive value of topoisomerase II alpha in randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). J Clin Oncol 2006; 24(18 suppl):11s (Abstract 533).
-
O'Malley F P, Chia S, Tu D, et al. Prognostic and predictive value of topoisomerase II alpha in randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). J Clin Oncol 2006; 24(18 suppl):11s (Abstract 533).
-
-
-
-
24
-
-
21044452025
-
Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant meth-ylation
-
Asano T, Nakamura K, Fujii H, et al. Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant meth-ylation. Br J Cancer 2005; 92:1486-92.
-
(2005)
Br J Cancer
, vol.92
, pp. 1486-1492
-
-
Asano, T.1
Nakamura, K.2
Fujii, H.3
-
25
-
-
33947317453
-
BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 neu positive early breast cancer patients
-
Abstract 52
-
Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 neu positive early breast cancer patients. Breast Cancer Res Treat 2006; 100(suppl 1): (Abstract 52).
-
(2006)
Breast Cancer Res Treat
, vol.100
, Issue.SUPPL. 1
-
-
Slamon, D.1
Eiermann, W.2
Robert, N.3
-
26
-
-
39149126730
-
HER-2 and topoisomerase II as predictors of response to chemotherapy
-
Pritchard KI, Messersmith H, Elavathil L, et al. HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 2008; 26:736-44.
-
(2008)
J Clin Oncol
, vol.26
, pp. 736-744
-
-
Pritchard, K.I.1
Messersmith, H.2
Elavathil, L.3
|